Hitachi Medical of Tokyo will use the RSNA meeting as a springboardin its plan to reenter the nuclear medicine market with directsales and marketing of digital gamma cameras it has manufacturedfor Summit Nuclear. Hitachi will describe the products as
Hitachi Medical of Tokyo will use the RSNA meeting as a springboardin its plan to reenter the nuclear medicine market with directsales and marketing of digital gamma cameras it has manufacturedfor Summit Nuclear. Hitachi will describe the products as works-in-progresson panels in its RSNA booth (SCAN 10/11/95).
Hitachi manufactured the single-head 1024RZ and the dual-headT-22 for Summit, which this year merged with Sopha Medical toform SMV (SCAN 6/21/95). SMV decided to deemphasize the Hitachi-madecameras in favor of systems of its own design.
Hitachi has updated the 1024RZ and T-22 cameras and is resubmittinga 510(k) application for them under the trade name SPECTRADigital.Hitachi is also planning to develop a digital variable-angle dual-headgamma camera for release next year.
In MRI, Hitachi will highlight enhancements to its Airis andStratis platforms, introduced at last year's meeting. A new softwarerelease for the open-configuration Airis and the MRP-7000 0.3-teslaconventional magnet will enable the use of new fast scanning andMR angiography packages. On the 1.5-tesla Stratis, Hitachi willshow phased-array coils and multishot echo-planar imaging as works-in-progress.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.